MCID: PLS006
MIFTS: 49

Plasmodium Vivax Malaria

Categories: Infectious diseases

Aliases & Classifications for Plasmodium Vivax Malaria

MalaCards integrated aliases for Plasmodium Vivax Malaria:

Name: Plasmodium Vivax Malaria 12 15 17 33
Malaria, Vivax 44 72
Malaria by Plasmodium Vivax 12
Vivax Malaria 12
Malaria Vivax 55

Classifications:



External Ids:

Disease Ontology 12 DOID:12978
ICD9CM 35 084.1
MeSH 44 D016780
NCIt 50 C34800
SNOMED-CT 68 27052006
UMLS 72 C0024537

Summaries for Plasmodium Vivax Malaria

Disease Ontology : 12 A malaria that is caused by the protozoan parasite Plasmodium vivax, which induces paroxysms at 48-hour intervals.

MalaCards based summary : Plasmodium Vivax Malaria, also known as malaria, vivax, is related to cardiogenic shock and pulmonary edema. An important gene associated with Plasmodium Vivax Malaria is ACKR1 (Atypical Chemokine Receptor 1 (Duffy Blood Group)), and among its related pathways/superpathways are TGF-Beta Pathway and Cytokine Signaling in Immune system. The drugs Primaquine and Sulfadoxine have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and neutrophil, and related phenotypes are cardiovascular system and cellular

Related Diseases for Plasmodium Vivax Malaria

Diseases related to Plasmodium Vivax Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 367)
# Related Disease Score Top Affiliating Genes
1 cardiogenic shock 31.1 TNF IL6
2 pulmonary edema 30.8 TNF IL10 ICAM1
3 bacterial infectious disease 30.7 TNF IL6 IL10 IFNG
4 plasmodium falciparum malaria 30.6 TNF IL10 IFNG ICAM1 G6PD
5 hemophagocytic lymphohistiocytosis 30.6 TNF IL10 IFNG
6 lyme disease 30.6 TNF IL6 CD40LG
7 typhoid fever 30.5 TNF IL6 IFNG
8 appendicitis 30.4 TNF IL6 IL10
9 bronchiolitis obliterans 30.3 TNF IL6 IL10 IFNG
10 bronchiolitis 30.3 TNF IL6 IL10 IFNG
11 dengue hemorrhagic fever 30.3 TNF IL6 IL10 IFNG
12 myocarditis 30.3 TNF IL6 ICAM1 CD40LG
13 leptospirosis 30.3 TNF IL6 IL10 IFNG
14 pneumonia 30.1 TNF IL6 IL10 CD40LG
15 echinococcosis 30.0 TNF IL6 IL10 IFNG
16 meningitis 30.0 TNF IL6 IL10 IFNG
17 malaria 29.9 TNF IL6 IL10 IFNG ICAM1 G6PD
18 adult respiratory distress syndrome 29.9 TNF IL6 IL10 ANGPT2
19 autoimmune disease 29.7 TNF IL6 IL10 IFNG CD40LG
20 brucellosis 29.4 TNF IL6 IL10 IFNG CD40LG
21 toxoplasmosis 29.4 TNF IL6 IL10 IFNG CD40LG
22 demyelinating disease 29.4 TNF IL10 IFNG ICAM1 CD40LG
23 thrombocytopenia 11.0
24 acute respiratory distress syndrome 10.9
25 glucosephosphate dehydrogenase deficiency 10.8
26 acute kidney failure 10.7
27 splenomegaly 10.7
28 scorpion envenomation 10.6 TNF IL6
29 staphylococcal toxic shock syndrome 10.6 TNF IFNG
30 hypoglycemia 10.6
31 angioimmunoblastic lymphadenopathy with dysproteinemia 10.6 TNF IL6
32 cytokine deficiency 10.6
33 chronic beryllium disease 10.6 TNF IFNG
34 trichosporonosis 10.6 TNF IFNG
35 streptococcal toxic-shock syndrome 10.6 TNF IL6
36 juvenile ankylosing spondylitis 10.6 TNF IL6
37 scleritis 10.6 TNF IFNG
38 punctate inner choroidopathy 10.6 TNF IL10
39 disseminated intravascular coagulation 10.6
40 b-cell growth factor 10.6 IL6 IFNG
41 null-cell leukemia 10.6 TNF IL6
42 tropical endomyocardial fibrosis 10.6 TNF IL10
43 endomyocardial fibrosis 10.6 TNF IL10
44 retinitis pigmentosa 55 10.6 TNF IL6
45 miliary tuberculosis 10.6 TNF IFNG
46 laryngitis 10.6 TNF IL6
47 glossitis 10.5 TNF IL6
48 exanthem 10.5
49 kidney disease 10.5
50 cephalosporin allergy 10.5 IL10 IFNG

Graphical network of the top 20 diseases related to Plasmodium Vivax Malaria:



Diseases related to Plasmodium Vivax Malaria

Symptoms & Phenotypes for Plasmodium Vivax Malaria

MGI Mouse Phenotypes related to Plasmodium Vivax Malaria:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 ANGPT2 CD40LG G6PD ICAM1 IFNG IL10
2 cellular MP:0005384 10.01 ANGPT2 CD40LG G6PD ICAM1 IFNG IL10
3 homeostasis/metabolism MP:0005376 9.97 ACKR1 ANGPT2 CD40LG G6PD ICAM1 IFNG
4 immune system MP:0005387 9.86 ACKR1 ANGPT2 CD40LG ICAM1 IFNG IL10
5 digestive/alimentary MP:0005381 9.85 ANGPT2 ICAM1 IFNG IL10 IL6 TNF
6 integument MP:0010771 9.7 ANGPT2 CD40LG ICAM1 IFNG IL10 IL6
7 neoplasm MP:0002006 9.35 ICAM1 IFNG IL10 IL6 TNF
8 vision/eye MP:0005391 9.1 ANGPT2 ICAM1 IFNG IL10 IL6 TNF

Drugs & Therapeutics for Plasmodium Vivax Malaria

Drugs for Plasmodium Vivax Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Primaquine Approved Phase 4 90-34-6 4908
2
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
3
leucovorin Approved Phase 4 58-05-9 143 6006
4
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Lumefantrine Approved Phase 4 82186-77-4 6437380
7
Artemether Approved Phase 4 71963-77-4 68911 119380
8
Mefloquine Approved, Investigational Phase 4 53230-10-7 4046
9
Artesunate Approved, Investigational Phase 4 88495-63-0 5464098 6917864
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11
Dihydroartemisinin Experimental, Investigational Phase 4 71939-50-9 6918483
12
Piperaquine Experimental, Investigational Phase 4 4085-31-8 5079497
13
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
14 Folic Acid Antagonists Phase 4
15 Renal Agents Phase 4
16 Vitamin B9 Phase 4
17 Folate Phase 4
18 Vitamin B Complex Phase 4
19 Anti-Infective Agents, Urinary Phase 4
20 Artemether, Lumefantrine Drug Combination Phase 4
21 Artemisinins Phase 4
22 Artemisinine Phase 4
23 Antiviral Agents Phase 4
24
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
25 Orange Approved Phase 3
26
Pyronaridine Investigational Phase 3 74847-35-1 5485198
27
Imidacloprid Vet_approved Phase 3 105827-78-9 86418
28
Methylene blue Approved, Investigational Phase 2 61-73-4
29
Tinidazole Approved, Investigational Phase 2 19387-91-8 5479
30
tafenoquine Approved, Investigational Phase 2 106635-80-7 115358
31 Alkylating Agents Phase 2
32 Anti-Bacterial Agents Phase 2
33 Fanasil, pyrimethamine drug combination Phase 2
34 Immunologic Factors Phase 2
35 Adjuvants, Immunologic Phase 2
36 Freund's Adjuvant Phase 2
37 Antibodies Phase 1, Phase 2
38 Immunoglobulins Phase 1, Phase 2
39 Vaccines Phase 2
40
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251
41
Ethinyl Estradiol Approved Phase 1 57-63-6 5991
42
Norgestimate Approved, Investigational Phase 1 35189-28-7 6540478
43
Moxifloxacin Approved, Investigational Phase 1 354812-41-2, 151096-09-2 152946
44
Polyestradiol phosphate Approved Phase 1 28014-46-2
45
Estradiol Approved, Investigational, Vet_approved Phase 1 50-28-2 5757
46
Metoprolol Approved, Investigational Phase 1 37350-58-6, 51384-51-1 4171
47
Ritonavir Approved, Investigational Phase 1 155213-67-5 392622
48 Pharmaceutical Solutions Phase 1
49 Natriuretic Agents Phase 1
50 diuretics Phase 1

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 An Open Label Randomized Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4 Artesunate;Chloroquine
2 Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam Unknown status NCT02610686 Phase 4 Chloroquine
3 A Randomised Controlled Trial to Assess the Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam Completed NCT01887821 Phase 4 Chloroquine;Dihydroartemisinin/Piperaquine
4 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Completed NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
5 Assessing Chloroquine Resistance of Plasmodium Vivax in Malaria Endemic Area Completed NCT02118090 Phase 4 Chloroquine sulfate;DHA-PP
6 Ethiopia Antimalarial in Vivo Efficacy Study 2012: Evaluating the Efficacy of Artemether-lumefantrine Alone Compared to Artemether-lumefantrine Plus Primaquine and Chloroquine Alone Compared to Chloroquine Plus Primaquine for Plasmodium Vivax Infection Completed NCT01680406 Phase 4 Artemether-lumefantrine combination;Primaquine;Chloroquine
7 A Study to Assess Current Standard Malaria Treatment Guidelines and Evaluate Recently Developed G6PD Diagnostic Tools in the Republic of the Sudan Completed NCT02592408 Phase 4 ASP;SDPQ;14DPQ;14DPQ on Day 42
8 A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of Glucose-6-dehydrogenase Status in South-east Bangladesh Completed NCT02389374 Phase 4 chloroquine;Artemether-lumefantrine combination;Primaquine;Primaquine
9 An Examination of ACT Strategy in South-central Asia on Falciparum Malaria in a Context Where Vivax is the Major Species Completed NCT00935688 Phase 4
10 Evaluation of Impact Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lempasing Village, Lampung Province, Southern Sumatra Completed NCT01389557 Phase 4 Dihydroartemisinin-piperaquine with primaquine
11 Comparison of the Effectiveness of Two Scheme Treatments to Treat Plasmodium Vivax Cases in Patients Living in Communities With Persistence of Transmission in Oaxaca and Chiapas, Mexico Completed NCT02394197 Phase 4 Chloroquine phosphate;primaquine
12 G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria Recruiting NCT02876549 Phase 4 Chloroquine;Primaquine 0.25 mg/kg/day;Primaquine 0.75 mg/kg weekly
13 Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas - a Randomized Controlled Trial Not yet recruiting NCT03916003 Phase 4 primaquine
14 Developing a Methodology to Assess 8-aminoquinoline Associated Haemolytic Risk in Females Heterozygous for G6PD in Endemic Populations Suspended NCT03337152 Phase 4 primaquine;chloroquine + primaquine
15 A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil Terminated NCT01107145 Phase 4 Mefloquine- Artesunate;Artemether-Lumefantrine;Chloroquine
16 Prevention of P. Vivax Malaria During Pregnancy: Effects on Mother and Child Health in Santa Cruz, Bolivia. Open, Multicentric, Randomized Clinical Trial, Comparing Prophylaxis Once a Week to Malaria Attack Treatment, Both by Chloroquine. Withdrawn NCT00290420 Phase 4 Chloroquine profilaxis
17 Artemether-lumefantrine vs Chloroquine in Patients With Acute Non-severe P. Vivax Malaria in Sabah, Malaysia Unknown status NCT02348788 Phase 3 Artemether-lumefantrine + Primaquine;Chloroquine + Primaquine
18 Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan Completed NCT01625871 Phase 3 tablets artemether/lumefantrine
19 A Phase III Multi-Centre, Randomised, Double-Blind, Double-Dummy, Comparative Clinical Study to Assess the Safety and Efficacy of a Fixed-Dose Formulation of Oral Pyronaridine Artesunate (180:60 mg Tablet) Versus Chloroquine (155 mg Tablet), in Children and Adult Patients With Acute Plasmodium Vivax Malaria Completed NCT00440999 Phase 3 Pyronaridine artesunate;Chloroquine
20 Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax Completed NCT01640574 Phase 3 Dihydroartemisinin-Piperaquine;Dihydroartemisinin-Piperaquine;Chloroquine;Chloroquine
21 Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup Completed NCT01288820 Phase 3 Dihydroartemisinin/piperaquine + primaquine;Artesunate-amodiaquine + primaquine
22 A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria Completed NCT02216123 Phase 3 Tafenoquine;Tafenoquine Placebo;Chloroquine;Primaquine;Primaquine Placebo
23 A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border Completed NCT01074905 Phase 3 Artesunate;Chloroquine;Chloroquine/Primaquine
24 Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan Completed NCT00682578 Phase 3 Dihydroartemisinin + Piperaquine (Artekin);artesunate-sulphadoxin/pyrimethamine, chloroquine
25 Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection Completed NCT02691910 Phase 2, Phase 3 Chloroquine;Primaquine
26 Artesunate-mefloquine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi and P. Vivax Malaria: a Randomized Open Label Trial in Sabah, Malaysia Completed NCT01708876 Phase 3 Artesunate-mefloquine;Chloroquine;Primaquine
27 Phase III Study to Study the Clinical Response to ACT Fixed Dose Combination in 42 Days in Uncomplicated Malaria in Cameroon Completed NCT01845701 Phase 3 Artesunate-Amodiaquine;Dihydroartemisinine-Piperaquine;Artemether-lumefantrine combination
28 An Open Label Randomized Comparative Study to Assess the Efficacy and Tolerability of Eurartesim® Versus Chloroquine and Nonrelapse Therapy With Primaquine for Uncomplicated Plasmodium Vivax Monoinfection Malaria Recruiting NCT03208907 Phase 3 CQ coadministered with PQ;DHA-PQP coadministered with PQ;CQ and PQ starting on Day 42;DHA-PQP and PQ starting on Day 42
29 Study 200894: A Double-blind, Double-dummy, Randomized, Parallel Group, Placebo-controlled Superiority Study to Evaluate the Efficacy and Safety of Tafenoquine (SB-252263, WR238605) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax Malaria Active, not recruiting NCT02802501 Phase 3 Tafenoquine;Matched-Placebo for Tafenoquine;Primaquine;Matched-Placebo for Primaquine;Dihydroartemisinin-piperaquine (DHA-PQP);ACT plus PQ (Rescue medication);PQ (End of study treatment)
30 Feasibility of Methylene Blue-based Combination Therapy in the Radical Treatment of Adult Patients With Plasmodium Vivax Malaria in Ethiopia: a Randomised Controlled Pilot Trial Unknown status NCT02696928 Phase 2 Artemeter-Lumefantrine and MB (combination therapy);Artemeter-Lumefantrine (combination therapy);Artemeter-Lumefantrine and Primaquine (combination therapy)
31 Phase IIa Exploratory, Open Label, Single/Multiple Dose Testing Clinical Study to Assess the Preliminary Efficacy, Tolerability and PK of OZ439 in Adult Patients With Acute, Uncomplicated P. Falciparum or Vivax Malaria Mono-infection Completed NCT01213966 Phase 2 OZ439
32 Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax Completed NCT00811096 Phase 2 Tinidazole;chloroquine
33 A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria. Completed NCT01376167 Phase 2 Chloroquine 600mg;Chloroquine 300mg;Tafenoquine 50mg;Tafenoquine 100mg;Tafenoquine 300mg;Tafenoquine 600mg;Primaquine 15mg;Chloroquine 600mg (Part 2 );Chloroquine 300mg (Part 2 );Tafenoquine 300mg (Part 2);Primaquine 15mg (Part2 )
34 A Randomised Non-Inferiority Trial of Sulfadoxine-Pyrimethamine Plus Artesunate Compared to Chloroquine for the Treatment of Vivax Malaria in Eastern Afghanistan. Completed NCT00486694 Phase 2 Sulfadoxine-pyrimethamine + artesunate;Chloroquine
35 A Proof-of-concept, Open Label, 3-day Repeated Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection Completed NCT01524341 Phase 2 KAE609
36 A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection Completed NCT01753323 Phase 2 KAF156
37 A Proof-of-Concept, Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Single Doses of DSM265 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-Infection Over a 35-Day-Extended Observation Period Completed NCT02123290 Phase 2 DSM265 400mg;DSM265 xmg;DSM265 ymg
38 Phase 1/2a Open-label Dose Safety, Reactogenicity, Immunogenicity and Efficacy of the Candidate Plasmodium Vivax Malaria Protein 001 (VMP001) Administered Intramuscularly With GlaxoSmithKline (GSK) Biologicals' Adjuvant System AS01B in Healthy Malaria-Naïve Adults Completed NCT01157897 Phase 1, Phase 2
39 Comparison of the Susceptibility of Naive and Pre-immune Volunteers to Infectious Challenge With Viable Plasmodium Vivax Sporozoites. Completed NCT01585077 Phase 1, Phase 2
40 Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax Completed NCT02083068 Phase 2
41 Phase 1 and Phase 2a Clinical Trial:Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites Completed NCT01082341 Phase 1, Phase 2
42 An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects With Plasmodium Vivax Malaria Recruiting NCT02563496 Phase 2 Tafenoquine;Chloroquine
43 Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in Glucose 6-phosphate Dehydrogenase Deficient Patients Recruiting NCT03529396 Phase 2 Chloroquine;Primaquine;Primaquine;Chloroquine;Primaquine
44 A Phase IIa Challenge Study to Assess Efficacy of the Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP and MVA PvDBP in Healthy Adults Living in the UK Not yet recruiting NCT04009096 Phase 2
45 An Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose of MMV390048 in Adult Patients With Acute, Uncomplicated Plasmodium Vivax or Falciparum Malaria Monoinfection Over a 35 Day Period Suspended NCT02880241 Phase 2 MMV390048
46 Proof of Concept Study of Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria Terminated NCT02110784 Phase 2 Eurartesim tablets
47 A Randomized, Active-control, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults Terminated NCT01290601 Phase 2 Tafenoquine;Chloroquine + Primaquine;tafenoquine;Chloroquine + Primaquine
48 Development of a Safe and Reproducible Human Sporozoite Challenge Model for Plasmodium Vivax in Healthy Adults in the United States Completed NCT00935623 Phase 1
49 A Five-cohort, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine (SB252263) 300mg When Co-administered With the Artemisinin-based Combination Therapies (ACT) Artemether + Lumefantrine (AL) and Dihydroartemisinin + Piperaquine Tetraphosphate (DHA+PQP) Completed NCT02184637 Phase 1 Tafenoquine;Dihydroartemisinin + Piperaquine tetraphosphate;Artemether + Lumefantrine
50 A Phase 1, Multi-center, Single-masked, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Ophthalmologic Safety and Pharmacodynamics of 300mg Single Doses of Tafenoquine (SB 252263) in Adult Healthy Volunteers Completed NCT02658435 Phase 1 Tafenoquine 150 mg;Matched placebo 150mg

Search NIH Clinical Center for Plasmodium Vivax Malaria

Inferred drug relations via UMLS 72 / NDF-RT 51 :


halofantrine
Halofantrine hydrochloride
Mefloquine
Mefloquine Hydrochloride
Primaquine
Primaquine
Primaquine Phosphate
Tafenoquine

Cochrane evidence based reviews: malaria, vivax

Genetic Tests for Plasmodium Vivax Malaria

Anatomical Context for Plasmodium Vivax Malaria

MalaCards organs/tissues related to Plasmodium Vivax Malaria:

41
Testes, T Cells, Neutrophil, Liver, Spleen, Kidney, Bone

Publications for Plasmodium Vivax Malaria

Articles related to Plasmodium Vivax Malaria:

(show top 50) (show all 1054)
# Title Authors PMID Year
1
FY polymorphisms and vivax malaria in inhabitants of Amazonas State, Brazil. 9 38
20162434 2010
2
[Clinical and laboratorial alterations in Plasmodium vivax malaria patients and glucose-6-phosphate dehydrogenase deficiency treated with primaquine at 0.50 mg/kg/day]. 9 38
15330059 2004
3
Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. 9 38
8036681 1994
4
Apical membrane protein 1-specific antibody profile and temporal changes in peripheral blood B-cell populations in Plasmodium vivax malaria. 38
31271660 2019
5
Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers. 38
31187437 2019
6
Five cases of Plasmodium vivax malaria treated with artemisinin derivatives: the advantages of a unified approach to treatment. 38
30809760 2019
7
Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report. 38
31399061 2019
8
The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. 38
31366382 2019
9
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. 38
30269312 2019
10
Duffy antigen receptor for chemokines (DARC) and susceptibility to Plasmodium vivax malaria. 38
30928426 2019
11
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria. 38
31274189 2019
12
Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria. 38
31366060 2019
13
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. 38
31327563 2019
14
Disseminated intravascular coagulation presenting as symmetrical peripheral gangrene: a case report. 38
31296267 2019
15
Genetic diversity and allelic variation in MSP3α gene of paired clinical Plasmodium vivax isolates from Delhi, India. 38
30824330 2019
16
Chronic hepatitis B virus infection drives changes in systemic immune activation profile in patients coinfected with Plasmodium vivax malaria. 38
31233500 2019
17
Plasmodium vivax Relapse Rates Following Plasmodium falciparum Malaria Reflect Previous Transmission Intensity. 38
30698794 2019
18
Epidemiology and distribution of Plasmodium vivax malaria in Sudan. 38
31162590 2019
19
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. 38
31067383 2019
20
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. 38
31067384 2019
21
Malaria impact on cognitive function of children in a peri-urban community in the Brazilian Amazon. 38
31096985 2019
22
Decreased uric acid levels in the acute phase of Plasmodium vivax malaria. 38
31141040 2019
23
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply. 38
31067385 2019
24
Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Guragae zone southern Central Ethiopia. 38
31088384 2019
25
Monitoring the Efficacy of Chloroquine-Primaquine Therapy for Uncomplicated Plasmodium vivax Malaria in the Main Transmission Hot Spot of Brazil. 38
30782991 2019
26
[A native mixed Plasmodium falciparum and Plasmodium vivax malaria case molecularly proven after 22 years in Manisa, Turkey]. 38
31130128 2019
27
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. 38
30952158 2019
28
Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia. 38
30940140 2019
29
Characterization of platelet count and platelet indices and their potential role to predict severity in malaria. 38
30967102 2019
30
High sensitivity methods to quantify chloroquine and its metabolite in human blood samples using LC-MS/MS. 38
30873854 2019
31
Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers. 38
30706164 2019
32
Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities. 38
30184203 2019
33
Molecular characterization and mapping of glucose-6-phosphate dehydrogenase (G6PD) mutations in the Greater Mekong Subregion. 38
30674319 2019
34
Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data. 38
30881061 2019
35
A Multi-Stage Plasmodium vivax Malaria Vaccine Candidate Able to Induce Long-Lived Antibody Responses Against Blood Stage Parasites and Robust Transmission-Blocking Activity. 38
31119106 2019
36
Chloroquine-Primaquine Therapeutic Efficacy, Safety, and Plasma Levels in Patients with Uncomplicated Plasmodium vivax Malaria in a Colombian Pacific Region. 38
30457097 2019
37
Profiles of hematological parameters in Plasmodium falciparum and Plasmodium vivax malaria patients attending Tercha General Hospital, Dawuro Zone, South Ethiopia. 38
30881057 2019
38
High Risk of Plasmodium vivax Malaria Following Splenectomy in Papua, Indonesia. 38
29771281 2019
39
Imported Plasmodium vivax Malaria in the Russian Federation from Western Sub-Saharan Africa. 38
30936925 2019
40
Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria. 38
30102351 2019
41
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. 38
30650322 2019
42
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. 38
30650326 2019
43
Evaluation of Plasmodium vivax malaria recurrence in Brazil. 38
30670020 2019
44
Epidemiological Characteristics of Re-emerging Vivax Malaria in the Republic of Korea (1993-2017). 38
30630273 2018
45
Concomitant Plasmodium vivax malaria and murine typhus infection with pulmonary involvement. 38
30567216 2018
46
New Evidence for Hypnozoite-Independent Plasmodium vivax Malarial Recurrences. 38
30213708 2018
47
Genetic characterization of Plasmodium vivax in the Kyrgyz Republic. 38
30339983 2018
48
Hemoglobin E protects against acute Plasmodium vivax infections in a Kachin population at the China-Myanmar border. 38
29964138 2018
49
Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study. 38
30442143 2018
50
Use of anthropophilic culicid-based xenosurveillance as a proxy for Plasmodium vivax malaria burden and transmission hotspots identification. 38
30418971 2018

Variations for Plasmodium Vivax Malaria

Expression for Plasmodium Vivax Malaria

Search GEO for disease gene expression data for Plasmodium Vivax Malaria.

Pathways for Plasmodium Vivax Malaria

Pathways related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.43 TNF IL6 IL10 IFNG ICAM1 ANGPT2
2
Show member pathways
13.25 TNF IL6 IL10 IFNG ICAM1 CD40LG
3
Show member pathways
12.73 TNF IL6 IL10 IFNG ICAM1 CD40LG
4
Show member pathways
12.54 TNF IL10 IFNG CD40LG
5
Show member pathways
12.51 TNF IL6 IL10 IFNG
6
Show member pathways
12.49 TNF IL6 IL10 IFNG ANGPT2
7 12.48 TNF IL10 IFNG CD40LG
8
Show member pathways
12.4 TNF IL6 IL10 IFNG CD40LG
9
Show member pathways
12.26 TNF IL6 IFNG ICAM1
10
Show member pathways
12.19 TNF IL10 IFNG CD40LG
11
Show member pathways
12.18 TNF IL6 IL10 IFNG
12 12.15 TNF IL6 IL10 IFNG
13
Show member pathways
12.12 TNF IL6 IL10
14 12.1 TNF IL6 IFNG
15
Show member pathways
12.1 TNF IL6 IFNG
16 12.09 TNF IL6 IL10
17 12.01 TNF IFNG ICAM1
18
Show member pathways
11.99 IL6 IL10 IFNG ICAM1 ANGPT2
19
Show member pathways
11.98 TNF IL6 IL10 IFNG
20
Show member pathways
11.96 TNF IL6 IFNG
21 11.93 TNF IL6 IFNG ICAM1
22 11.9 TNF IL6 ICAM1
23 11.9 TNF IL6 IL10 IFNG
24 11.88 IL6 IFNG ANGPT2
25 11.88 TNF IL6 IL10 ICAM1
26 11.84 TNF IL6 ICAM1
27 11.84 TNF ICAM1 CD40LG
28 11.81 IL6 IL10 IFNG
29 11.8 TNF IL6 IL10 IFNG
30 11.75 TNF IL6 IFNG ICAM1
31 11.74 IL6 IFNG ICAM1
32 11.73 TNF IL10 IFNG
33 11.7 TNF IL6 IL10
34
Show member pathways
11.69 TNF IFNG CD40LG
35 11.6 TNF IL6 IL10 IFNG
36 11.56 TNF IL6 IL10 IFNG
37 11.51 TNF IL6 IFNG
38 11.47 TNF IL6 ICAM1
39 11.43 TNF IL6 IFNG
40
Show member pathways
11.35 TNF IL6 IFNG ICAM1 CD40LG
41 11.31 TNF IL6 IL10
42 11.31 TNF IL6 IL10 ICAM1
43 11.26 TNF IL6 IFNG
44 11.13 IL10 IFNG
45 11.11 IFNG ICAM1
46 11.04 TNF IL6
47 11.02 TNF IL6 IL10 IFNG
48 11 TNF IL6 IL10 CD40LG ANGPT2
49 10.97 TNF IL6
50 10.93 TNF IL6 IL10 CD40LG ANGPT2

GO Terms for Plasmodium Vivax Malaria

Cellular components related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 TNF IL6 IL10 IFNG ICAM1 CD40LG

Biological processes related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.87 TNF IL6 IL10 ICAM1
2 immune response GO:0006955 9.85 TNF IL6 IL10 IFNG CD40LG
3 response to organic cyclic compound GO:0014070 9.79 ICAM1 G6PD ANGPT2
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.76 TNF IL6 IL10
5 response to glucocorticoid GO:0051384 9.72 TNF IL6 IL10
6 humoral immune response GO:0006959 9.67 TNF IL6 IFNG
7 positive regulation of protein complex assembly GO:0031334 9.64 TNF IFNG
8 positive regulation of interleukin-12 production GO:0032735 9.64 IFNG CD40LG
9 negative regulation of neurogenesis GO:0050768 9.63 TNF IL6
10 positive regulation of osteoclast differentiation GO:0045672 9.63 TNF IFNG
11 positive regulation of chemokine production GO:0032722 9.62 TNF IL6
12 positive regulation of glial cell proliferation GO:0060252 9.62 TNF IL6
13 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.61 TNF IFNG
14 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.61 TNF IL10 DDX39B
15 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.6 TNF IL10
16 negative regulation of growth of symbiont in host GO:0044130 9.59 TNF IL10
17 negative regulation of lipid storage GO:0010888 9.58 TNF IL6
18 positive regulation of nitric oxide biosynthetic process GO:0045429 9.58 TNF IFNG ICAM1
19 endothelial cell apoptotic process GO:0072577 9.56 TNF IL10
20 cellular response to lipopolysaccharide GO:0071222 9.56 TNF IL6 IL10 ICAM1
21 positive regulation of neuroinflammatory response GO:0150078 9.54 TNF IL6
22 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.52 TNF ICAM1
23 negative regulation of cytokine secretion involved in immune response GO:0002740 9.51 TNF IL10
24 regulation of immunoglobulin secretion GO:0051023 9.48 TNF CD40LG
25 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.46 TNF IL6 ICAM1 CD40LG
26 receptor biosynthetic process GO:0032800 9.37 TNF IL10
27 inflammatory response GO:0006954 9.35 TNF IL6 IL10 CD40LG ACKR1
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 TNF IFNG
29 positive regulation of vitamin D biosynthetic process GO:0060557 8.62 TNF IFNG

Molecular functions related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 TNF IL6 IL10 IFNG CD40LG

Sources for Plasmodium Vivax Malaria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....